var data={"title":"Baclofen: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Baclofen: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5699?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=baclofen-patient-drug-information\" class=\"drug drug_patient\">see &quot;Baclofen: Patient drug information&quot;</a> and <a href=\"topic.htm?path=baclofen-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Baclofen: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708644\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Abrupt withdrawal (injection): </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Abrupt discontinuation of intrathecal baclofen, regardless of the cause, has resulted in sequelae that include high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, which in rare cases has advanced to rhabdomyolysis, multiple organ-system failure, and death.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms. Advise patients and caregivers of the importance of keeping scheduled refill visits and educate them on the early symptoms of baclofen withdrawal. Give special attention to patients at apparent risk (eg, spinal cord injuries at T-6 or above, communication difficulties, history of withdrawal symptoms from oral or intrathecal baclofen). Consult the technical manual of the implantable infusion system for additional postimplant clinician and patient information.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138898\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>EnovaRX-Baclofen;</li>\n      <li>Equipto-Baclofen;</li>\n      <li>First-Baclofen 1;</li>\n      <li>First-Baclofen 5;</li>\n      <li>Gablofen;</li>\n      <li>Lioresal;</li>\n      <li>Lioresal Intrathecal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138899\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Baclofen;</li>\n      <li>Dom-Baclofen;</li>\n      <li>Lioresal;</li>\n      <li>Lioresal D.S.;</li>\n      <li>Lioresal Intrathecal;</li>\n      <li>Mylan-Baclofen;</li>\n      <li>Novo-Baclofen;</li>\n      <li>PHL-Baclofen;</li>\n      <li>PMS-Baclofen;</li>\n      <li>ratio-Baclofen;</li>\n      <li>Riva-Baclofen;</li>\n      <li>VPI-Baclofen Intrathecal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138942\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Skeletal Muscle Relaxant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138901\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Spasticity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> Initial: 5 mg 3 times daily; may increase by 5 mg per dose  every 3 days (ie, 5 mg 3 times daily for 3 days, then 10 mg 3 times daily for 3 days, etc.) until optimal response is reached. Usual dosage range: 40 to 80 mg daily.  Do not exceed 80 mg daily (20 mg 4 times daily).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intrathecal:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Screening dose: Initial: 50 mcg for 1 dose; following initial administration, observe patient for 4 to 8 hours. A positive response consists of a significant decrease in muscle tone and/or frequency and/or severity of spasms.  If response is inadequate, may give 75 mcg as a second screening dose 24 hours after the first screening dose; observe patient for 4 to 8 hours. If response is still inadequate, may repeat a final screening dose of 100 mcg given 24 hours after the second screening dose. Patients not responding to screening dose of 100 mcg should not be considered for chronic infusion/implanted pump.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose titration following pump implant: After positive response to screening dose, a maintenance intrathecal infusion can be administered via an implanted intrathecal pump.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial total daily dose via pump: Double the screening dose that gave a positive response and administer over 24 hours, unless efficacy of the bolus dose was maintained for &gt;8 hours, then infuse a dose equivalent to the screening dose over 24 hours. Do not increase dose in first 24 hours (to allow steady state to be achieved); thereafter, dosage adjustments may be made by increasing daily dose slowly by 10% to 30% (spasticity of spinal cord origin) or 5% to 15% (spasticity of cerebral origin) once every 24 hours until satisfactory response.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Daily dose may be increased 5% to 20% (maximum increase: 20%) (spasticity of cerebral origin) or by 10% to 40% (maximum increase: 40%) (spasticity of spinal cord origin). Dose may also be decreased 10% to 20% for adverse effects. Most patients have been adequately maintained on 90 mcg to 703 mcg daily (spasticity of cerebral origin) or 300 mcg to 800 mcg daily (spasticity of spinal cord origin). Experience with doses &gt;1,000 mcg daily is limited.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Dosage adjustments may be required often during the first few months of therapy to adjust for life style changes due to alleviation of spasticity. Maintain lowest dose that produces adequate response.  Most patients require gradual increases over time to maintain optimal response. Sudden large requirements for a dose increase may indicate a catheter complication (eg, kink, dislodgement).Titrate dose to allow sufficient muscle tone and occasional spasms to optimize activities of daily living, support circulation, and possibly prevent DVT formation. <b>Use extreme caution when filling the pump; follow manufacturer instructions carefully.</b> 5% to 10% of patients receiving chronic therapy become refractory to dose adjustments; may consider a drug holiday (hospitalized patients only) with a gradual withdrawal over 2 to 4 weeks and use of alternative spasticity management methods. Following the drug holiday intrathecal baclofen may be resumed at the initial continuous infusion dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alcoholic liver disease, alcohol abstinence (off-label use):</b> Oral: Initial: 5 mg 3 times daily for 3 days; Maintenance: 10 mg 3 times daily (AASLD [Runyon 2012]; Addolorato 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastroesophageal reflux disease (off-label use):</b> Oral: 10 mg 4 times daily (Ciccaglione 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hiccups (off-label use):</b> Oral: 5 to 10 mg 3 times daily (maximum: 75 mg daily in divided doses) (Guelaud 1995; Zhang 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nystagmus (off-label use):</b> Oral: 5 mg 3 times daily; may increase at weekly intervals until optimal response is reached or intolerable adverse effects occur. Dosage range studied: 15 to 120 mg daily in divided doses (Cormer 2006; Dieterich 1991). Additional data may be necessary to further define the role of baclofen in the treatment of this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Trigeminal neuralgia (off-label use):</b> Oral: Initial: 5 to 10 mg 3 times daily (dose may be as low as 10 mg daily); may increase dose by 10 mg every other day over 1 to 2 weeks. Dosage range studied: 30 to 80 mg daily in 3 to 4 divided doses (Fromm 1984). Additional data may be necessary to further define the role of baclofen in the treatment of this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138920\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=baclofen-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Baclofen: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: <b>Note:</b> Use the lowest effective dose; patients who fail to respond within a reasonable amount of time should be slowly withdrawn from therapy (avoid abrupt withdrawal of drug).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Spasticity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents (off-label): <b>Note:</b> Dose-related side effects (eg, sedation) may be minimized by slow titration; lower initial doses than described below (2.5 to 10 mg <b>daily</b>) may be used with subsequent titration to 8 hourly doses. There is limited published data in infants and children; the following is a compilation of small prospective studies (Milla 1977; Scheinberg 2006) and one large retrospective analysis of baclofen use in children (Lubsch 2006). Efficacy results variable (AAN [Delgado] 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;4 months and Children &lt;2 years: Limited data available: 10 to 20 mg <b>daily</b> divided every 8 hours; begin at low end of range and titrate dose to patient response, titration intervals of every 3 days to weekly have been used in pediatric patients &ge;2 years (Millia 1997; Scheinberg 2006). Maximum daily dose: 40 mg/<b>day</b> (Lubsch 2006). <b>Note:</b> To minimize dose-related side effects (eg, sedation), lower initial doses (eg, 2.5 mg once daily) and slower titration may be considered (eg, weekly) and has been reported in pediatric patients &gt;2 years (Scheinberg 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2 to 7 years: Limited data available: 20 to 40 mg <b>daily</b> divided every 8 hours; begin at low end of range (or even lower [2.5 to 10 mg <b>daily</b>] and titrate dose to patient response; titration intervals of every 3 days to weekly have been used in pediatric patients. Maximum daily dose: 60 mg/day (Lubsch 2006; Millia 1997; Scheinberg 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;8 years and Adolescents: Limited data available in children &lt;12 years: 30 to 40 mg <b>daily</b> divided every 8 hours; begin at low end of range (or even lower [10 mg to 15 mg <b>daily</b> in 3 divided doses]) and titrate dose to patient response, titration intervals of every 3 days to weekly have been used (Millia 1997; Scheinberg 2006); some patients &ge;12 years may require every 6 hour dosing; usual maximum daily dose range: 60 to 80 mg/<b>day</b> (Lubsch 2006; Millia 1977). <b>Note:</b> Higher maximum daily doses (up to 200 mg/day) have been described in some patients in a retrospective review, usually the higher doses were needed over time (Lubsch 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intrathecal:</i> Children &ge;4 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Screening dose: Refer to adult dosing. <b>Note:</b> A 25 mcg initial screening dose may be considered in very small pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose titration following pump implant: After positive response to screening dose, a maintenance intrathecal infusion can be administered via an implanted intrathecal pump.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial total daily dose via pump: Double the screening dose that gave a positive response and administer over 24 hours, unless efficacy of the bolus dose was maintained for &gt;8 hours, then infuse a dose equivalent to the screening dose over 24 hours. Do not increase dose in first 24 hours (to allow steady state to be achieved); thereafter, increase daily dose slowly by 5% to 15% once every 24 hours until satisfactory response.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Daily dose may be increased 5% to 20% (maximum increase: 20%). Dose may also be decreased 10% to 20% for adverse effects. Patients &lt;12 years required lower daily doses in clinical trials (average dose: 274 mcg daily; dosage range: 24 mcg to 1,199 mcg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Dosage adjustments may be required often during the first few months of therapy to adjust for life style changes due to alleviation of spasticity. Maintain lowest dose that produces adequate response.  Most patients require gradual increases over time to maintain optimal response. Sudden large requirements for a dose increase may indicate a catheter complication (eg, kink, dislodgement).Titrate dose to allow sufficient muscle tone and occasional spasms to optimize activities of daily living, support circulation, and possibly prevent DVT formation. <b>Use extreme caution when filling the pump; follow manufacturer instructions carefully.</b> 5% to 10% of patients receiving chronic therapy become refractory to dose adjustments; may consider a drug holiday (hospitalized patients only) with a gradual withdrawal over 2 to 4 weeks and use of alternative spasticity management methods. Following the drug holiday intrathecal baclofen may be resumed at the initial continuous infusion dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138902\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Refer to adult dosing; use with caution. If benefits are not observed, withdraw the drug slowly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138903\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, baclofen is primarily eliminated renally; use with caution; dosage reduction may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The following dosage adjustments have been recommended (Vlavonou 2014; renal function estimated using the Cockcroft-Gault formula):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;80 mL/minute: No initial dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 50 to 80 mL/minute: Initial: 5 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to &lt;50 mL/minute: Initial: 2.5 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute (not on dialysis): Initial: 2.5 mg every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD on hemodialysis: Avoid use (based on case reports; Chen 1997; El-Husseini 2011; Lee 2013; Su 2009); if baclofen must be used, initiate at a low dose with careful monitoring for toxicity (Lee 2013). Baclofen is readily removed by hemodialysis, with a report of 79% removal in a 4 hour session (Roberts 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:2em;\">Intrathecal: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, baclofen is primarily renally eliminated; use with caution; dosage reduction may be necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682666\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral and intrathecal: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138875\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EnovaRX-Baclofen: 1% (60 g, 120 g) [contains cetyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Equipto-Baclofen: 2% (120 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2% (60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intrathecal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gablofen: 40,000 mcg/20 mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intrathecal [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gablofen: 10,000 mcg/20 mL (20 mL); 20,000 mcg/20 mL (20 mL) [antioxidant free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lioresal: 0.05 mg/mL (1 mL); 10 mg/20 mL (20 mL [DSC]); 10 mg/5 mL (5 mL [DSC]); 40 mg/20 mL (20 mL [DSC]) [antioxidant free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lioresal Intrathecal: 40 mg/20 mL (20 mL) [antioxidant free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lioresal Intrathecal: 500 mcg/mL (20 mL); 2000 mcg/mL (5 mL) [antioxidant free, pyrogen free]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intrathecal [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gablofen: 50 mcg/mL (1 mL) [antioxidant free, latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gablofen: 50 mcg/mL (1 mL [DSC]); 10,000 mcg/20 mL (20 mL [DSC]); 40,000 mcg/20 mL (20 mL [DSC]); 20,000 mcg/20 mL (20 mL) [antioxidant free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gablofen: 10,000 mcg/20 mL (20 mL); 40,000 mcg/20 mL (20 mL) [antioxidant free, pyrogen free]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Baclofen 1: 1 mg/mL (120 mL) [contains saccharin sodium, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Baclofen 5: 5 mg/mL (60 mL, 120 mL) [contains saccharin sodium, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138861\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23884414\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EnovaRX-Baclofen and Equipto-Baclofen creams are compounded from kits. Refer to manufacturer&rsquo;s labeling for compounding instructions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">First-Baclofen suspension is a compounding kit. Refer to manufacturer&rsquo;s labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138878\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrathecal: For screening dosages, administer as a bolus injection (50 mcg/mL concentration) by barbotage into the subarachnoid space over at least 1 minute, followed by maintenance continuous infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer without regards to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138877\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Spasticity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Management of reversible spasticity associated with multiple sclerosis or spinal cord lesions </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intrathecal: Management of severe spasticity of spinal cord origin (eg, spinal cord injury, multiple sclerosis) or cerebral origin (eg, cerebral palsy, traumatic brain injury)  in patients &ge;4 years; may be considered as an alternative to destructive neurosurgical procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Limitations of use: Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25721978\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Alcoholic liver disease (alcohol abstinence); Gastroesophageal reflux disease (adults); Hiccups (singultus); Nystagmus; Trigeminal neuralgia; Spasticity in cerebral palsy (children/adolescents) (short-term treatment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138951\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Baclofen may be confused with Bactroban </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lioresal may be confused with lisinopril, Lotensin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138868\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Hypotonia (2% to 35%), drowsiness (6% to 21%), confusion (1% to 11%), headache (2% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (1% to 12%), vomiting (2% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (&le;9%), peripheral edema (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Seizure (&le;10%), dizziness (2% to 8%), insomnia (&le;7%), paresthesia (&le;7%), hypertonia (&le;6%), pain (&le;4%), speech disturbance (&le;4%), depression (2%), coma (&le;2%), abnormality in thinking (&le;1%), agitation (&le;1%), chills (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (4%), urticaria (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (&le;6%), sialorrhea (&le;3%), xerostomia (&le;3%), diarrhea (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary retention (&le;8%), urinary frequency (&le;6%), difficulty in micturition (2%), impotence (&le;2%), urinary incontinence (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (&le;2%), weakness (&le;2%), tremor (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Ambylopia (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Hypoventilation (&le;4%), pneumonia (&le;2%), dyspnea (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, accommodation disturbance, akathisia, albuminuria, alopecia, amnesia, ankle edema, anorexia, anxiety, apnea, ataxia, blurred vision, bradycardia, carcinoma, chest pain, contact dermatitis, decreased libido, deep vein thrombophlebitis, dehydration, dermal ulcer, diaphoresis, diplopia, dysarthria, dysautonomia, dysgeusia, dysphagia, dystonia, dysuria, epilepsy, erectile dysfunction, euphoria, excitement, facial edema, fecal incontinence, fever, gastrointestinal hemorrhage, hallucination, hematuria, hyperglycemia, hyperhidrosis, hypertension, hyperventilation, hypothermia, hysteria, inhibited ejaculation, intestinal obstruction, leukocytosis, loss of postural reflex, malaise, miosis, muscle rigidity, myalgia, mydriasis, nasal congestion, nephrolithiasis, nocturia, nystagmus, occult blood in stools, oliguria, opisthotonus, orgasm disturbance, pallor, palpitations, paranoia, personality disorder, petechial rash, priapism, pulmonary embolism, scoliosis, scoliosis progression, sedation, sexual disorder, skin rash, slurred speech, strabismus, suicidal ideation, syncope, taste disorder, tinnitus, tongue irritation, vaginitis, vasodilatation, weight gain, weight loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138882\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to baclofen or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrathecal: IV, IM, SubQ, or epidural administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138865\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intrathecal mass: Cases (most from pharmacy compounded preparations) of intrathecal mass formation at the implanted catheter tip have been reported; patients may experience worsening or return of spasticity, pain, inadequate response to dose adjustments, and/or neurological deficit/dysfunction. Neurosurgical evaluation and/or an appropriate imaging study should be considered if a mass is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary retention: May cause acute urinary retention (may be related to underlying disease); use with caution in patients with urinary obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autonomic dysreflexia: Use intrathecal baclofen with caution in patients with a history of autonomic dysreflexia; presence of nociceptive stimuli or abrupt baclofen withdrawal may cause an autonomic dysreflexic episode.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disorders: Use with caution in patients with peptic ulcer disease, decreased GI motility, and/or gastrointestinal obstructive disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disease: Use with caution in patients with psychotic disorders, schizophrenia, or confusional states; may cause exacerbation of condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; baclofen is eliminated primarily unchanged via the kidneys. Multiple cases describing neurotoxicity due to oral baclofen accumulation in adult patients with varying levels of renal impairment have been reported in the literature. In patients with renal impairment, initiation of oral baclofen at lower doses and/or extended intervals has been suggested (Aisen 1994; Chen 1997; Chou 2006; El-Husseini 2011; Peces 1998; Su 2009; Vlavonu 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; monitor regularly for loss of seizure control. Seizures have been reported with withdrawal from intrathecal baclofen as well as in patients maintained on therapeutic doses of intrathecal baclofen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; may be more sensitive to adverse CNS effects, especially at higher doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Intrathecal: Children should be of sufficient body mass to accommodate the implantable pump for chronic infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abrupt withdrawal: <b>[US Boxed Warning]: Abrupt withdrawal of intrathecal baclofen, regardless of the cause, has resulted in sequelae (hyperpyrexia, altered mental status, exaggerated rebound spasticity, and muscle rigidity, which, in rare cases, has advanced to rhabdomyolysis), multiple organ-system failure, and death. Prevention of abrupt discontinuation requires careful attention to programming and monitoring of infusion system, refill scheduling and procedures, and pump alarms. </b><b>Advise patients and caregivers of the importance of keeping scheduled refill visits and educate them on the early symptoms of baclofen withdrawal. Give special attention to patients at apparent risk (eg, spinal cord injuries at T-6 or above, communication difficulties, history of withdrawal symptoms from oral or intrathecal baclofen). Consult the technical manual of the implantable infusion system for additional postimplant clinician and patient information. </b> In most cases, symptoms of withdrawal (eg, return of baseline spasticity, hypotension, paresthesia, pruritus) appear within hours to a few days following interruption of therapy. Priapism may develop or recur if treatment with intrathecal baclofen is interrupted. Clinically, the advanced intrathecal baclofen withdrawal syndrome may resemble autonomic dysreflexia, infection (sepsis), malignant hyperthermia, neuroleptic-malignant syndrome, or other conditions associated with a hypermetabolic state or widespread rhabdomyolysis. Suggested treatment for intrathecal baclofen withdrawal is restoration of intrathecal baclofen at or near the same dosage as before therapy was interrupted. Abrupt withdrawal of oral therapy has been associated with hallucinations and seizures; gradual dose reductions (over ~1 to 2 weeks) are recommended in the absence of severe adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Intrathecal: For use only in an FDA-approved implantable pump for intrathecal baclofen administration; health care providers should be experienced with chronic intrathecal infusion therapy and resuscitative equipment should be readily available. Ensure patient is infection-free and then evaluate patient&rsquo;s response to bolus intrathecal injection (screening phase) prior to implanting pump. Monitor closely during the initial phase of pump use and when adjusting the dosing rate and/or the concentration in the reservoir. Educate patients and caregivers on proper home care of the pump and insertion site. Use extreme caution when filling an implantable pump; pumps should only be refilled through the reservoir refill septum. Inadvertent injection into the subcutaneous tissue can occur if the reservoir refill septum is not properly accessed. Some pumps are equipped with a catheter access port that allows direct access to the intrathecal catheter; direct injection into this catheter access port or inadvertent injection into the subcutaneous tissue may cause a life-threatening overdose. Except in overdose related emergencies, intrathecal baclofen should be reduced slowly if discontinuation is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Oral: Efficacy of oral baclofen has not been established in patients with stroke, Parkinson disease, or cerebral palsy; therefore, use is not recommended. Not indicated for spasticity associated with rheumatic disorders. Use with caution when spasticity is utilized to sustain upright posture and balance in locomotion, or when spasticity is necessary to obtain increased function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Overdose: Intrathecal use: Monitor closely for signs and symptoms of overdose which may appear suddenly or insidiously, especially during the initial screening and dose-titration phase of treatment, and during reintroduction of therapy after a period of interruption. Signs/symptoms of overdose may include drowsiness, dizziness, somnolence, hypothermia, respiratory depression, seizures, rostral progression of hypotonia and loss of consciousness progressing to coma. If overdose is suspected, patient should be evaluated immediately in a hospital setting and the pump reservoir emptied.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298810\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138870\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9062&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacidipine: Baclofen may enhance the hypotensive effect of Lacidipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolperisone: May enhance the adverse/toxic effect of Muscle Relaxants (Centrally Acting). Management: Monitor for increased sedation or CNS effects if tolperisone is combined with other centrally acting muscle relaxants. Consider decreasing the tolperisone dose if these agents are combined.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138872\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13273272\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Withdrawal symptoms in the neonate were noted in a case report following the maternal use of oral baclofen 20 mg 4 times/day throughout pregnancy (Ratnayaka 2001). Plasma concentrations following administration of intrathecal baclofen are significantly less than those with oral doses; exposure to the fetus is expected to be limited (Morton 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13273273\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Baclofen is excreted in breast milk. Very small amounts were found in the breast milk of a woman 14 days postpartum after oral use. Following a single oral dose of baclofen 20 mg, the total amount of baclofen excreted in breast milk within 26 hours was 22 mcg (Eriksson 1981). Adverse events were not observed in a nursing infant following maternal use of intrathecal baclofen 200 mcg/day throughout pregnancy and while nursing (Morton 2009). Due to the potential for adverse events in the nursing infant, breast-feeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26641845\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Regular electroencephalogram (EEG) in patients with epilepsy (loss of seizure control has been reported).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138864\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits the transmission of both monosynaptic and polysynaptic reflexes at the spinal cord level, possibly by hyperpolarization of primary afferent fiber terminals, with resultant relief of muscle spasticity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138881\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Intrathecal bolus: 30 minutes to 1 hour; Continuous infusion: 6 to 8 hours after infusion initiation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Intrathecal bolus: 4 hours (effects may last 4 to 8 hours); Continuous infusion: 24 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption (dose dependent): Oral: Rapid; absorption from the GI tract is thought to be dose dependent; in pediatric patients (age range: 2 to 17 years) with cerebral palsy, absorption from GI tract highly variable and delayed (reported time lag: 0.59 &plusmn; 0.28 hours) (He 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: 74% (Agarwal 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Volume of distribution: Pediatric patients (age range: 2 to 17 years: Oral: Highly variable: 1.16 L/kg with 43.5% interindividual variability (He 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic (15% of dose) (He 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pediatric patients with cerebral palsy (age range: 2 to 17 years): 4.5 hours (He 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 3.75 &plusmn; 0.96 hours (Brunton 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intrathecal: CSF elimination half-life: 1.51 hours over the first 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: 1 hour (0.5 to 4 hours) (Brunton 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&gt;70% as unchanged drug) and feces (Brunton 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138884\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Baclofen External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (60 g): $240.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Equipto-Baclofen External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (120 g): $579.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gablofen Intrathecal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 mcg/20 mL (20 mL): $258.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20000 mcg/20 mL (20 mL): $516.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40000 mcg/20 mL (20 mL): $1,032.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lioresal Intrathecal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/mL (1 mL): $36.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lioresal Intrathecal Intrathecal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/20 mL (20 mL): $1,032.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg/mL (20 mL): $258.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 mcg/mL (5 mL): $258.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Gablofen Intrathecal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/mL (1 mL): $96.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 mcg/20 mL (20 mL): $277.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20000 mcg/20 mL (20 mL): $554.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40000 mcg/20 mL (20 mL): $1,110.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (First-Baclofen 1 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (120 mL): $42.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (First-Baclofen 5 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (60 mL): $52.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Baclofen Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $247.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $513.03</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038536\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alpha-Baclofen (NZ);</li>\n      <li>Baclan (KR);</li>\n      <li>Baclofen-ratiopharm (LU);</li>\n      <li>Baclofene (FR);</li>\n      <li>Baclon (FI, LK, TW);</li>\n      <li>Baclopar (IE);</li>\n      <li>Baclosal (IL, LV);</li>\n      <li>Baclosan (RU);</li>\n      <li>Baclosol (VN);</li>\n      <li>Bacofen (KR);</li>\n      <li>Bacron (KR);</li>\n      <li>Bamifen (VN);</li>\n      <li>Barapa (KR);</li>\n      <li>Clofen (AU);</li>\n      <li>Colmifen (MT, SG);</li>\n      <li>Curofen (KR);</li>\n      <li>Diafen (PY, UY);</li>\n      <li>Espast (PE);</li>\n      <li>Flexibac (LK);</li>\n      <li>Gabalon (JP);</li>\n      <li>Liobac (TH);</li>\n      <li>Liorel (BD);</li>\n      <li>Lioresal (AE, AR, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CN, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KW, LB, LK, LR, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PH, PK, PL, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SL, SN, SR, SY, TH, TN, TR, TT, TZ, UG, VE, YE, ZA, ZM, ZW);</li>\n      <li>Lioresyl (CL);</li>\n      <li>Liosal (BD);</li>\n      <li>Lyflex (GB, IE);</li>\n      <li>Miorel (GR);</li>\n      <li>Mulax (TW);</li>\n      <li>Mylinax (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Myorel (LK);</li>\n      <li>Onelaxant-R (PH);</li>\n      <li>Pacifen (NZ, TW);</li>\n      <li>Prex (KR);</li>\n      <li>Skelofen (BD);</li>\n      <li>Slaken (BD);</li>\n      <li>Solofen (TW);</li>\n      <li>Spinax (TW);</li>\n      <li>Stelax (AU, HK);</li>\n      <li>Trilaxant (PH);</li>\n      <li>Yylofen (VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abarbanel J, Herishanu Y, Frisher S, &ldquo;Encephalopathy Associated With Baclofen,&rdquo; <i>Ann Neurol</i>, 1985, 17(6):617-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/4026235/pubmed\" target=\"_blank\" id=\"4026235\">4026235</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18068515\"></a>Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomized, double-blind controlled study. <i>Lancet</i>. 2007;370:1915-1922.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/18068515/pubmed\" target=\"_blank\" id=\"18068515\">18068515</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25028414\"></a>Agarwal SK, Kriel RL, Cloyd JC, et al. A pilot study assessing pharmacokinetics and tolerability of oral and intravenous baclofen in healthy adult volunteers. J Child Neurol. 2015;30(1):37-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/25028414/pubmed\" target=\"_blank\" id=\"25028414\">25028414</a>]</span><span class=\"doi\">10.1177/0883073814535504</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aisen ML, Dietz M, McDowell F, Kutt H. Baclofen toxicity in a patient with subclinical renal insufficiency. <i>Arch Phys Med Rehabil</i>. 1994;75(1):109-111.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/8291951/pubmed\" target=\"_blank\" id=\"8291951\">8291951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albright AL, &ldquo;Baclofen in Treatment of Cerebral Palsy,&rdquo; <i>J Child Neurol</i>, 1996, 11(2):77-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/8881981/pubmed\" target=\"_blank\" id=\"8881981\">8881981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baclofen tablet [prescribing information]. Pulaski, TN: AvKare Inc; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brunton LL, Chabner BA, Knollmann BC, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 12th ed. New York, NY: McGraw-Hill Medical; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chen KS, Bullard MJ, Chien YY, Lee SY. Baclofen toxicity in patients with severely impaired renal function. <i>Ann Pharmacother</i>. 1997;31(11):1315-1320.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/9391686/pubmed\" target=\"_blank\" id=\"9391686\">9391686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chou CL, Chen CA, Lin SH, Huang HH. Baclofen-induced neurotoxicity in chronic renal failure patients with intractable hiccups. <i>South Med J</i>. 2006;99(11):1308-1309.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/17195438/pubmed\" target=\"_blank\" id=\"17195438\">17195438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. <i>Gut. </i>2003;52(4):464-470.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/12631652/pubmed\" target=\"_blank\" id=\"12631652\">12631652</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooke DE and Glasstone MA, &ldquo;Baclofen Poisoning in Children,&rdquo; <i>Vet Hum Toxicol</i>, 1994, 36(5):448-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/7839572/pubmed\" target=\"_blank\" id=\"7839572\">7839572</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Comer RM, Dawson EL, Lee JP. Baclofen for patients with congenital periodic alternating nystagmus. <i>Strabismus</i>. 2006;14(4):205-209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/17162442/pubmed\" target=\"_blank\" id=\"17162442\">17162442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dieterich M, Straube A, Brandt T, Paulus W, B&uuml;ttner U. The effects of baclofen and cholinergic drugs on upbeat and downbeat nystagmus. <i>J Neurol Neurosurg Psychiatry</i>. 1991;54(7):627-632.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/1654396/pubmed\" target=\"_blank\" id=\"1654396\">1654396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    El-Husseini A, Sabucedo A, Lamarche J, Courville C, Peguero A. Baclofen toxicity in patients with advanced nephropathy: proposal for new labeling. <i>Am J Nephrol</i>. 2011;34(6):491-495.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/22041434/pubmed\" target=\"_blank\" id=\"22041434\">22041434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eriksson G and Swahn CG, &quot;Concentrations of Baclofen in Serum and Breast Milk From a Lactating Woman,&quot; <i>Scand J Clin Lab Invest</i>, 1981, 41(2):185-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/7313501/pubmed\" target=\"_blank\" id=\"7313501\">7313501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. <i>Ann Neurol</i>. 1984;15(3):240-244.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/6372646/pubmed\" target=\"_blank\" id=\"6372646\">6372646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gablofen (baclofen) [prescribing information]. Bethlehem, PA: Primal Critical Care Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guelaud C, Similowski T, Bizec JL, Cabane J, Whitelaw WA, Derenne JP. Baclofen therapy for chronic hiccup. <i>Eur Respir J</i>. 1995;8(2):235-237.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/7758557/pubmed\" target=\"_blank\" id=\"7758557\">7758557</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    He Y, Brunstrom-Hernandez JE, Thio LL, et al. Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy. <i>J Pediatr</i>. 2014;164(5):1181-1188.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khorasani A and Peruzzi WT, &ldquo;Dantrolene Treatment for Abrupt Intrathecal Baclofen Withdrawal,&rdquo; <i>Anesth Analg</i>, 1995, 80(5):1054-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/7726408/pubmed\" target=\"_blank\" id=\"7726408\">7726408</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee J, Shin HS, Jung YS, et al. Two cases of baclofen-induced encephalopathy in hemodialysis and peritoneal dialysis patients. <i>Ren Fail</i>. 2013;35(6):860-862. P<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/23682655/pubmed\" target=\"_blank\" id=\"23682655\">23682655</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lioresal Intrathecal (baclofen) [prescribing information]. Roswell, GA: Saol Therapeutics Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lioresal Intrathecal (baclofen) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lubsch L, Habersang R, Haase M, et al, &ldquo;Oral Baclofen and Clonidine for Treatment of Spasticity in Children,&rdquo; <i>J Child Neurol</i>, 2006, 21(12):1090-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/17156708/pubmed\" target=\"_blank\" id=\"17156708\">17156708</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    May CR, &ldquo;Baclofen Overdose,&rdquo; <i>Ann Emerg Med</i>, 1983, 12:171-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/6829997/pubmed\" target=\"_blank\" id=\"6829997\">6829997</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Milla PJ and Jackson AD, &ldquo;A Controlled Trial of Baclofen in Children With Cerebral Palsy,&rdquo; <i>J Int Med Res</i>, 1977, 5(6):398-404.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/338390/pubmed\" target=\"_blank\" id=\"338390\">338390</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morton CM, Rosenow J, Wong C, et al, &quot;Intrathecal Baclofen Administration During Pregnancy: A Case Series and Focused Clinical Review,&quot; <i>PM R</i>, 2009, 1(11):1025-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/19942189/pubmed\" target=\"_blank\" id=\"19942189\">19942189</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peces R, Navascu&eacute;s RA, Baltar J, Laur&eacute;s AS, Alvarez-Grande J. Baclofen neurotoxicity in chronic haemodialysis patients with hiccups. <i>Nephrol Dial Transplant</i>. 1998;13(7):1896-1897.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/9681766/pubmed\" target=\"_blank\" id=\"9681766\">9681766</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quality Standards Subcommittee of the American Academy of Neurology (AAN) and the Practice Committee of the Child Neurology Society, Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. <i>Neurology</i>. 2010;74(4):336-343.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/20101040/pubmed\" target=\"_blank\" id=\"20101040\">20101040</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ratnayaka BD, Dhaliwal H, and Watkin S, &quot;Drug Points: Neonatal Convulsions After Withdrawal of Baclofen,&quot; <i>BMJ</i>, 2001, 323(7304):85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/11451783/pubmed\" target=\"_blank\" id=\"11451783\">11451783</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberge RJ, Martin TG, Hodgman M, et al, &ldquo;Supraventricular Tachyarrhythmia Associated With Baclofen Overdose,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1994, 32(3):291-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/8007036/pubmed\" target=\"_blank\" id=\"8007036\">8007036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts JK, Westphal S, Sparks MA. Iatrogenic Baclofen Neurotoxicity in ESRD: Recognition and Management. <i>Semin Dial</i>. 2015;28(5):525-529. doi: 10.1111/sdi.12400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/26096760/pubmed\" target=\"_blank\" id=\"26096760\">26096760</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Runyon BA; American Association for the Study of Liver Diseases. Practice guideline: management of adult patients with ascites due to cirrhosis: update 2012. http://aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf. Accessed May 6, 2015.23463403</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scheinberg A, Hall K, Lam LT, et al, &ldquo;Oral Baclofen in Children With Cerebral Palsy: A Double-Blind Cross-Over Pilot Study,&rdquo; <i>J Paediatr Child Health</i>, 2006, 42(11):715-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/17044900/pubmed\" target=\"_blank\" id=\"17044900\">17044900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Su W, Yegappan C, Carlisle EJ, Clase CM. Reduced level of consciousness from baclofen in people with low kidney function. <i>BMJ</i>. 2009;339:b4559.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/20044395/pubmed\" target=\"_blank\" id=\"20044395\">20044395</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tan AK and Tan CB, &ldquo;The Syndrome of Painful Legs and Moving Toes - A Case Report,&rdquo; <i>Singapore Med J</i>, 1996, 37(4):446-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/8993154/pubmed\" target=\"_blank\" id=\"8993154\">8993154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vlavonou R, Perreault MM, Barri&egrave;re O, et al. Pharmacokinetic characterization of baclofen in patients with chronic kidney disease: dose adjustment recommendations. <i>J Clin Pharmacol</i>. 2014;54(5):584-592.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/24414993/pubmed\" target=\"_blank\" id=\"24414993\">24414993</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhang C, Zhang R, Zhang S, Xu M, Zhang S. Baclofen for stroke patients with persistent hiccups: a randomized, double-blind, placebo-controlled trial. <i>Trials</i>. 2014;15:295.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/baclofen-drug-information/abstract-text/25052238/pubmed\" target=\"_blank\" id=\"25052238\">25052238</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9062 Version 234.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708644\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F138898\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F138899\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F138942\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F138901\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F138920\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F138902\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F138903\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682666\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F138875\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F138861\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F23884414\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F138878\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F138877\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25721978\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F138951\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F138868\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F138882\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F138865\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298810\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F138870\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F138872\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13273272\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13273273\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F26641845\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F138864\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F138881\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F138884\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038536\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9062|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=baclofen-patient-drug-information\" class=\"drug drug_patient\">Baclofen: Patient drug information</a></li><li><a href=\"topic.htm?path=baclofen-pediatric-drug-information\" class=\"drug drug_pediatric\">Baclofen: Pediatric drug information</a></li></ul></div></div>","javascript":null}